CTRI/2022/07/044180招募中未知
A randomized, single-blind, placebo-controlled study to evaluate the efficacy andsafety of Nigellin in individuals with allergic rhinitis.
试验速览
- 阶段
- 未知
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or Female in the age of 18 to 60 years.
- •2. At least 2 or more allergic symptoms: sneezing, rhinorrhoea, nasal obstruction, and nasal itching for a cumulative period greater than 1 hour per day. These symptoms may be accompanied by tears, itchy, swelling & red eyes.
- •3. Patients with a medical history of allergic rhinitis.
- •4. Voluntary written consent.
排除标准
- •1. Known chronic diseases such as asthma, rhinosinusitis, nasal polyposis
- •2. Known severe medical conditions, such as cardiovascular, liver or renal dysfunction, diabetes mellitus, cancers, cerebrovascular diseases, and blood system diseases.
- •3. Concomitant steroid, anticoagulant, and immunotherapy within the past 1 month.
- •4. Impaired haematological profile and liver / renal function.
- •5. Known alcohol and / or drug abuse.
- •6. Participants who are pregnant or lactating
- •7. History of serious allergic reaction to investigational product
- •8. Participant has participated in any clinical trial within the last 3 months
- •9. Any other condition which the Principal Investigator thinks may jeopardize the study.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAGiant Cell ArteritisEUCTR2017-002988-18-SESanofi-Aventis Recherche & Développement508
进行中（未招募）
不适用
A clinical study to evaluate the efficacy and tolerability of a novel herbal composition to relieve constipation and to improve bowel clearanceCTRI/2022/09/046036Bohan and Co
进行中（未招募）
1 期
Evaluation of the Efficacy and Safety of Sarilumab in Patients with Polymyalgia RheumaticaPolymyalgia rheumaticaEUCTR2017-002989-42-DKSanofi-Aventis Recherche & Développement500
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAGiant Cell ArteritisEUCTR2017-002988-18-DKSanofi-Aventis Recherche & Développement508
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without STsegmentelevation - SOLSTICESubjects with myocardial infarction without ST-segment elevationMedDRA version: 9.1Level: LLTClassification code 10064347Term: Non ST segment elevation myocardial infarctionEUCTR2009-010615-32-NLGlaxoSmithKline R&D Ltd400